Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Anika Therapeutics (ANIK) EPS (Weighted Average and Diluted) (2016 - 2026)

Anika Therapeutics has reported EPS (Weighted Average and Diluted) over the past 17 years, most recently at -$0.37 for Q1 2026.

  • Quarterly EPS (Weighted Average and Diluted) fell 8.82% to -$0.37 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$0.8 through Mar 2026, up 58.97% year-over-year, with the annual reading at -$0.76 for FY2025, 80.16% up from the prior year.
  • EPS (Weighted Average and Diluted) was -$0.37 for Q1 2026 at Anika Therapeutics, down from $0.06 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at $144.29 in Q2 2024 and troughed at -$1.49 in Q4 2024.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$0.29 (2022), against an average of $8.23.
  • Year-over-year, EPS (Weighted Average and Diluted) crashed 825.0% in 2022 and then skyrocketed 76044.27% in 2024.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.34 in 2022, then soared by 426.47% to $1.11 in 2023, then crashed by 234.23% to -$1.49 in 2024, then skyrocketed by 104.03% to $0.06 in 2025, then crashed by 716.67% to -$0.37 in 2026.
  • Per Business Quant, the three most recent readings for ANIK's EPS (Weighted Average and Diluted) are -$0.37 (Q1 2026), $0.06 (Q4 2025), and -$0.16 (Q3 2025).